Fate of Intercept's NASH drug clouded by murky FDA review delays

Fate of Intercept's NASH drug clouded by murky FDA review delays

More reads

• As approval decision nears, fate of Intercept’s NASH drug clouded by murky FDA review delays. (STAT Plus)
• Biotech suddenly bests FAANG stocks in rally to all-time high. (Bloomberg)
• A pill to fight alcoholism causes an uproar in France over a regulator’s view of a clinical trial. (STAT Plus)